the results of cross-linking with riboflavin/uv-a in patients with progressive keratoconus
Clicks: 180
ID: 183441
2016
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
174 views
19 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Objective: To evaluate the results of corneal cross-linking with UV-A/riboflavin in patients with progressive keratoconus.
Methods: Forty-seven eyes of 30 patients with progressive keratoconus (16 female, 14 male) were included in the study. Uncorrected and the best corrected distance visual acuities, biomicroscopic findings, intraocular pressure measurements, fundoscopic findings, pachymetric measurements and corneal topography parameters were recorded for each patient.
Results: The mean age of the patients was 18.3±5.34 (range: 8-31) years and the mean follow-up duration was 7±2.4 (range: 3-12) months. Following the procedure, the mean decrease in K1, K2, Kav, spherical and cylindrical values were 0.77 D, 0.85 D, 0.80 D, 0.50 D and 0.74 D, respectively (p<0.05). There were no cases with decrease in visual acuity and significant complication during or after the treatment.
Conclusion: Cross-linking with riboflavin/UV-A in patients with progressive keratoconus is an effective procedure. In addition, the preservation of visual acuity and not seen a significant complication indicate that a safe metod. However, large prospective randomized controlled studies are needed to evaluate the long-term effects of this treatment.
| Reference Key |
kaydu2016diclethe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Erdal Kaydu;İbrahim Erbağcı;Seydi Okumuş;Ümit Aksoy |
| Journal | journal of sulfur chemistry |
| Year | 2016 |
| DOI |
10.5798/diclemedj.0921.2016.01.0640
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.